<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cesarean scar pregnancy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cesarean scar pregnancy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cesarean scar pregnancy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ilan E Timor-Tritsch, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lynn L Simpson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 16, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1470546305"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cesarean scar pregnancy (CSP) refers to a pregnancy that is implanted on or in a scar from a prior cesarean birth. A pregnancy implanted on or in a myomectomy scar (also referred to as intramural pregnancy) can also occur; for the purposes of this topic, the term CSP will be used for all hysterotomy scar pregnancies. If unrecognized or inadequately managed, CSP can lead to severe fetal and maternal morbidity (eg, uterine rupture, hemorrhage) and mortality.</p><p>CSP is likely a precursor to, and shares common histology with, placenta accreta spectrum (PAS). The two conditions may represent a continuum of the same disease, with CSP being a diagnosis of the first (and early second) trimester, and PAS being diagnosed later in pregnancy (second trimester and beyond). Like PAS, the rate of CSP parallels that of cesarean birth and is expected to rise as the rate of cesarean birth increases and as the diagnostic accuracy of imaging for CSP improves.</p><p>By contrast, CSP is distinct from ectopic pregnancy as CSP occurs within uterine cavity and can result in a live born infant, which rarely, if ever, occurs in an ectopic pregnancy. Thus, treatments appropriate for ectopic pregnancy should not be used indiscriminately to treat or manage CSP.</p><p>This topic will focus on issues related to CSP. The diagnosis and management of PAS, as well as other abnormally implanted pregnancies (eg, abdominal, cervical, tubal, heterotopic), are discussed in detail separately.</p><p class="bulletIndent1"><span class="glyph">●</span>PAS (see  <a class="medical medical_review" href="/z/d/html/6759.html" rel="external">"Placenta accreta spectrum: Clinical features, diagnosis, and potential consequences"</a> and  <a class="medical medical_review" href="/z/d/html/83129.html" rel="external">"Placenta accreta spectrum: Management"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abdominal pregnancy (see  <a class="medical medical_review" href="/z/d/html/132045.html" rel="external">"Abdominal pregnancy"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cervical pregnancy (see  <a class="medical medical_review" href="/z/d/html/3283.html" rel="external">"Cervical pregnancy: Diagnosis and management"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tubal and heterotopic pregnancies (see  <a class="medical medical_review" href="/z/d/html/5481.html" rel="external">"Ectopic pregnancy: Epidemiology, risk factors, and anatomic sites"</a> and  <a class="medical medical_review" href="/z/d/html/5487.html" rel="external">"Ectopic pregnancy: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/112852.html" rel="external">"Ectopic pregnancy: Choosing a treatment"</a>)</p><p></p><p class="headingAnchor" id="H4043297032"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>There are two main types of CSPs [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>"<strong>On-the-scar"</strong> <strong>(type 1)</strong> – Implantation of the CSP on the well-healed scar of a previous cesarean birth (also termed "endogenous" implantation).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>"In-the-niche"</strong> <strong>(type 2)</strong> – Implantation of the CSP within the defect or "niche" of an incompletely healed scar (also termed "niche pregnancy," or "exogenous" implantation).</p><p></p><p>Clinical outcomes appear to be more favorable for "on-the-scar" compared with "in-the-niche" CSP; however, most ultrasound reports and published studies do not specify CSP type. (See <a class="local">'Natural history'</a> below and <a class="local">'Expectant management'</a> below.)</p><p>Other classification systems have been described [<a href="#rid2">2,3</a>]. </p><p class="headingAnchor" id="H228432150"><span class="h1">INCIDENCE</span><span class="headingEndMark"> — </span>CSP occurs in approximately 1 in 2000 pregnancies and accounts for approximately 6 percent of abnormally implanted pregnancies among patients with a prior cesarean birth [<a href="#rid4">4-6</a>]. The incidence appears to be rising; in a 10-year review at one institution in China, the number of patients with CSPs increased from three in the initial five years (2004 to 2008) to 19 in the following five years (2009 to 2013) [<a href="#rid7">7</a>].</p><p>It is the author's impression that, like placenta accreta spectrum (PAS), incidence correlates with the number of previous cesarean deliveries; however, there are no data to support or refute this theory. There are also no data regarding the incidence of CSP by type (ie, "on-the-scar" [type 1] versus "in-the-niche" [type 2]). (See <a class="local">'Classification'</a> above.)</p><p>The incidence of pregnancies implanted at the site of a prior myomectomy scar is rare [<a href="#rid8">8,9</a>]. </p><p>Multiple gestations with a coexistent CSP have also been described [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H2682535016"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The mechanism for implantation of a CSP is unclear; various theories include: the endogenous migration of the embryo through either a wedge defect in the lower uterine segment or a microscopic fistula within the scar [<a href="#rid11">11,12</a>]; invasion of placental villi into the uterine wall at a point of scar dehiscence [<a href="#rid13">13-15</a>]; low oxygen tension of scar tissue attracting implantation of the fertilized oocyte [<a href="#rid16">16</a>].</p><p>Some experts believe that CSP is a precursor to, and shares a common histology with, placenta accreta spectrum (PAS) and that they are a continuum of the same disease [<a href="#rid17">17-19</a>]. Both involve the placenta attaching to or invading the myometrium, almost always in an area of scarring caused by previous uterine surgery. While PAS is typically a diagnosis made in the second trimester, some experts believe that sonographic findings may be present in the first trimester, further strengthening the association of PAS with CSP [<a href="#rid20">20-24</a>].</p><p>Representative studies supporting this theory include:</p><p class="bulletIndent1"><span class="glyph">●</span>In a literature review including seven studies with 551 pregnant patients at risk for PAS, at least one ultrasound marker suggestive of PAS (eg, low anterior implantation of the gestational sac, placental lacunae, reduced myometrial thickness) was detected in 91 percent of patients with a confirmed diagnosis [<a href="#rid23">23</a>]. Low anterior implantation of the placenta was the most commonly seen early ultrasound sign suggestive of PAS (83 percent of cases), although its individual predictive accuracy was not high.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In one series including 10 patients with a diagnosis of CSP made prior to 10 weeks gestation, all patients exhibited signs of PAS by the second trimester [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study including 58 cases of CSP and PAS where histologic specimens were independently reviewed by two pathologists who were blinded to each other's findings, they agreed that, on the basis of histology, it was impossible to differentiate between the two diseases [<a href="#rid18">18</a>].</p><p></p><p>The pathogenesis and ultrasound findings of PAS are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6759.html" rel="external">"Placenta accreta spectrum: Clinical features, diagnosis, and potential consequences", section on 'Pathogenesis'</a> and  <a class="medical medical_review" href="/z/d/html/6759.html" rel="external">"Placenta accreta spectrum: Clinical features, diagnosis, and potential consequences", section on 'First-trimester ultrasound examination'</a>.)</p><p class="headingAnchor" id="H1153184617"><span class="h1">NATURAL HISTORY</span><span class="headingEndMark"> — </span>CSPs are associated with high morbidity early in pregnancy (eg, hemorrhage, uterine rupture, placenta accreta spectrum [PAS]) and even maternal mortality. However, some CSPs may continue to a viable gestation. Series describing outcomes of expectantly managed CSPs all involve small case numbers and high hysterectomy rates.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Uterine rupture</strong> – CSPs are predisposed to early (ie, first- or second-trimester) uterine rupture [<a href="#rid25">25</a>]. In a meta-analysis including 17 studies (69 patients) evaluating the outcomes of patients with CSP that were managed expectantly, early uterine rupture in patients with and without embryonic/fetal cardiac activity occurred in 9.9 to 13.4 percent (95% CI 2.9-20.4 and 2.7-30.3) of patients, respectively [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1">In our experience, uterine rupture occurs more frequently in those implanted "in-the-niche" (ie, type 2) rather than "on-the-scar" (type 1).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Delivery of a live born neonate</strong> <strong>and hysterectomy rates</strong> – Rates of delivery of live born neonates and hysterectomy vary.</p><p></p><p class="bulletIndent1">In one series including 10 patients with a diagnosis of CSP made prior to 10 weeks gestation and described above (see <a class="local">'Pathogenesis'</a> above), nine patients (90 percent) delivered live born neonates between 32 and 37 weeks of gestation all of whom delivered by cesarean hysterectomy; mean blood loss was 1560 mL (range 300 to 6000 mL) and two patients required a blood transfusion [<a href="#rid17">17</a>]. One patient experienced cervical shortening and intractable vaginal bleeding prompting termination (with hysterectomy) at 20 weeks gestation. Placenta percreta was the histopathological diagnosis in all 10 cases.</p><p></p><p class="bulletIndent1">Lower rates have been reported [<a href="#rid26">26,27</a>]. In a retrospective study including eight patients diagnosed with a live CSP diagnosed prior to 14 weeks gestation and choosing expectant management, five patients (63 percent) delivered a live-born neonate between 29 and 36 weeks of gestation, of whom three (60 percent) required cesarean-hysterectomy [<a href="#rid27">27</a>]. The remaining three patients experienced a subsequent fetal demise; no patients with fetal demise required hysterectomy.</p><p></p><p class="bulletIndent1">Outcomes may be more favorable for "on the scar" compared with "in-the-niche" CSPs, but data are limited as most studies do not specify CSP type. (See <a class="local">'Expectant management'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Enhanced myometrial vascularity </strong>– CSP may be associated with the development of enhanced myometrial vascularity (EMV; a distinct entity from arteriovenous malformation, which occurs in nonpregnant patients) [<a href="#rid28">28-30</a>], and treatments that leave the pregnancy in place (eg, balloon catheters) may increase this risk (see <a class="local">'Medical therapy'</a> below). In one retrospective study including 60 patients with CSP, five patients (8 percent) with persistent and/or severe bleeding were subsequently diagnosed with an EMV; further management with uterine artery embolization (UAE; four patients) or hysterectomy (one patient) was required [<a href="#rid31">31</a>].</p><p></p><p>Other outcomes associated with CSPs that progress to, or near, term are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6759.html" rel="external">"Placenta accreta spectrum: Clinical features, diagnosis, and potential consequences", section on 'Consequences'</a>.)</p><p class="headingAnchor" id="H466783199"><span class="h1">RISK FACTORS</span></p><p class="headingAnchor" id="H2140065378"><span class="h2">History of CSP</span><span class="headingEndMark"> — </span>The risk of recurrent CSP may be more common than previously thought and ranges from 5 to 40 percent; this is based mostly on single case reports or series with few patients [<a href="#rid32">32,33</a>]. The true rate is unknown.</p><p>In one meta-analysis including 44 studies (3598 patients) evaluating subsequent reproductive outcomes in patients with a prior CSP, recurrence occurred in 17.6 percent of patients [<a href="#rid32">32</a>]. When stratified according to management type, recurrence of CSP was more common in patients undergoing surgical compared with nonsurgical management (90 of 428 patients [21 percent] versus 21 of 138 patients [15 percent], respectively). One limitation of this study is that subgroup analyses according to the type of surgical (eg, uterine curettage, uterine resection) or nonsurgical (eg, systematic <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> [MTX], local injection of MTX or <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">potassium chloride</a> [KCl], uterine artery embolization) procedure were not performed.</p><p class="headingAnchor" id="H413976542"><span class="h2">Other</span><span class="headingEndMark"> — </span>Other factors that may contribute to the risk of CSP in patients with a prior cesarean birth include [<a href="#rid4">4,8,34</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Other previous uterine surgery (eg, dilation and curettage [D&amp;C], endometrial ablation)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Manual removal of the placenta</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In vitro fertilization</p><p></p><p class="headingAnchor" id="H3256379765"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Approximately one-third of patients with CSP are asymptomatic at the time of ultrasound diagnosis [<a href="#rid35">35</a>].</p><p>For patients with symptoms, vaginal bleeding is the most common symptom and usually presents in the late first or early second trimester. However, symptoms can range from vaginal bleeding with or without abdominal/pelvic pain to uterine rupture with hypovolemic shock [<a href="#rid34">34,36-38</a>].</p><p>In one retrospective study including 22 patients with CSP, the presenting symptom was vaginal bleeding alone (86 percent), vaginal bleeding with abdominal pain (9 percent), or abdominal pain alone (4.5 percent) [<a href="#rid7">7</a>]. This is consistent with a subsequent retrospective study including 20 patients with CSP in which most patients (90 percent) presented with either vaginal bleeding and/or abdominal pain; two patients (10 percent) were asymptomatic at the time of diagnosis [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H3712748878"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H3182220395"><span class="h2">Definitive diagnosis</span><span class="headingEndMark"> — </span>CSP is a diagnosis made based on first- (or early second-) trimester transvaginal ultrasound (TVUS) findings of a pregnancy implanted on or in a prior hysterotomy scar/niche and confirmed at the time of surgery with histologic findings consistent with placenta accreta spectrum (PAS) disorder. (See  <a class="medical medical_review" href="/z/d/html/6759.html" rel="external">"Placenta accreta spectrum: Clinical features, diagnosis, and potential consequences", section on 'Postpartum placental histology'</a>.)</p><p>TVUS combined with color Doppler evaluation is the preferred imaging modality in patients with CSP and has superior resolution compared with transabdominal ultrasound.</p><p class="headingAnchor" id="H267982052"><span class="h2">Findings suggestive of the diagnosis</span><span class="headingEndMark"> — </span>Early ultrasound findings suggestive of CSP in a patient with a prior uterine scar include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low anterior position of the gestational</strong> <strong>sac at ≤7 weeks</strong> – A low anterior position of the gestational sac is an ultrasound marker for CSP only at very early gestational ages (ie, between five and seven weeks of gestation) [<a href="#rid40">40</a>]. After seven to nine weeks of gestation, the gestational sac "pushes" into the uterine cavity (leaving behind the implanted placenta) as this is the only available place for the sac (with the embryo/fetus) to expand into.</p><p></p><p class="bulletIndent1">The following method can be used to determine location of the gestation sac  (<a class="graphic graphic_diagnosticimage graphicRef134095" href="/z/d/graphic/134095.html" rel="external">image 1</a>) [<a href="#rid41">41</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>On a panoramic, longitudinal, sagittal scan, divide the uterus in half by an imaginary line perpendicular to its longitudinal axis and determine the location of the gestational sac related to this line.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mark the center of the gestational sac.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the center of the sac is above the aforementioned line (closer to the uterine fundus), it is most likely an intrauterine pregnancy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the center of the sac is below the line (closer to the cervix), it is a CSP (or, in rare cases, a cervical pregnancy). (See <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p class="bulletIndent1">When applied at or before seven weeks of gestation, this method has reliable statistical performance (sensitivity: 93 percent, specificity: 98.9 percent, positive predictive value: 96.4 percent, negative predictive value: 97.9 percent) [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1">An exception is for patients with a prior classical incision or fundal incision (during myomectomy). For such patients, the CSP is likely to develop in the upper, rather than lower, portion of the uterus.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other findings</strong> – Other findings are consistent with PAS and include one or more of the following [<a href="#rid40">40,42,43</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Low-lying anterior placenta or placenta previa – A low-lying anterior placenta or placenta previa  (<a class="graphic graphic_diagnosticimage graphicRef134077" href="/z/d/graphic/134077.html" rel="external">image 2</a>) increases the risk of persistent placenta previa and PAS in patients with a prior cesarean birth. As with other patients with PAS, attention should be directed at determining the extent of invasion into adjacent pelvic structures (eg, bladder, cervix, parametria), if present [<a href="#rid44">44,45</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Placental lacunae  (<a class="graphic graphic_diagnosticimage graphicRef134074" href="/z/d/graphic/134074.html" rel="external">image 3</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Thin (&lt;3 mm) or no intervening myometrium/clear space between the placenta and bladder or anterior uterine serosa  (<a class="graphic graphic_diagnosticimage graphicRef134073" href="/z/d/graphic/134073.html" rel="external">image 4</a>). This distance is also termed residual myometrial thickness [RMT] and is the only quantifiable ultrasound marker of CSP.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Irregular or disrupted bladder line or anteriorly bulging sac into the bladder  (<a class="graphic graphic_diagnosticimage graphicRef134075" href="/z/d/graphic/134075.html" rel="external">image 5</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased vascularity at the bladder/placental interphase  (<a class="graphic graphic_diagnosticimage graphicRef134076" href="/z/d/graphic/134076.html" rel="external">image 6</a>).</p><p></p><p>When present, these findings (with the exception of the low anterior position of the gestation sac) become increasingly evident as the pregnancy progresses from five to seven weeks of gestation to the end of the first trimester [<a href="#rid46">46,47</a>]. (See  <a class="medical medical_review" href="/z/d/html/6759.html" rel="external">"Placenta accreta spectrum: Clinical features, diagnosis, and potential consequences", section on 'Ultrasound findings'</a>.)</p><p class="headingAnchor" id="H1886905376"><span class="h2">Other imaging techniques</span><span class="headingEndMark"> — </span>Three-dimensional ultrasound rarely contributes to the diagnosis of CSP; however, if expertly used, it may aid in the diagnosis in some patients [<a href="#rid48">48,49</a>].</p><p>There is no evidence to support the routine use of other imaging modalities, such as pelvic magnetic resonance imaging (MRI), to diagnosis CSP [<a href="#rid50">50</a>]. However, in cases in which ultrasound imaging is indeterminate or the ultrasound images are suboptimal, MRI may be used for further evaluation.</p><p class="headingAnchor" id="H961456862"><span class="h1">DIFFERENTIAL DIAGNOSIS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Cervical pregnancy – Cervical pregnancy is a rare form of ectopic pregnancy and can be differentiated from CSP by the finding of a gestational sac or placenta within the cervix on transvaginal ultrasound (TVUS). (See  <a class="medical medical_review" href="/z/d/html/3283.html" rel="external">"Cervical pregnancy: Diagnosis and management", section on 'Transvaginal ultrasound'</a>.)</p><p></p><p class="bulletIndent1">Unlike CSP, cervical pregnancy almost always occurs in patients <strong>without</strong> a history of a prior cesarean birth. In our experience, patients with a history of prior uterine surgery and with a finding of gestational sac in a low anterior position and/or a low-lying anterior placenta have a CSP and not a cervical pregnancy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Early pregnancy loss – In patients undergoing an early pregnancy loss (ie, miscarriage, spontaneous abortion), a single ultrasound may demonstrate a gestational sac or placenta in the lower uterine segment; fetal cardiac activity is usually absent. In patients with a prior uterine scar, this may be confused with a CSP. However, for patients undergoing a pregnancy loss, subsequent ultrasound examinations will typically show the pregnancy even lower in the uterus, in the cervical canal, or an empty uterus (in the case of a complete abortion). Additional ultrasound findings that support a diagnosis of early pregnancy loss are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/130879.html" rel="external">"Pregnancy loss (miscarriage): Ultrasound diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intrauterine pregnancy – While an intrauterine pregnancy with an unusually low implantation of the gestational sac may raise suspicion for a CSP, CSP can essentially be ruled out in patients without a history of previous cesarean birth.</p><p></p><p>In a literature review including 751 cases of CSP, misdiagnosis of CSP as a cervical ectopic pregnancy or miscarriage occurred in 13.6 percent of patients; the delay in diagnosis potentially resulted in a large number of additional complications (eg, hemorrhage, shock, hemoperitoneum) with some requiring hysterectomy for definitive surgical management [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H2554723583"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>This section describes the management of CSP in the first and early second trimesters. At later gestations, these pregnancies are managed the same as placenta accreta spectrum (PAS), which is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/83129.html" rel="external">"Placenta accreta spectrum: Management"</a>.)</p><p>As with PAS, patients with CSP should transferred, whenever possible, to a center of excellence for PAS, or a tertiary care hospital in which maternal-fetal medicine specialists, a variety of treatment options (eg, uterine artery embolization [UAE]), and blood bank services are available.</p><p class="headingAnchor" id="H1971316495"><span class="h2">Hemodynamically unstable patients</span><span class="headingEndMark"> — </span>A patient with hemorrhage and existing or impending hemodynamic instability requires immediate surgical intervention (eg, wedge resection, gravid hysterectomy) and/or a minimally invasive procedure (ie, UAE). (See <a class="local">'Surgical therapy'</a> below and <a class="local">'Adjunctive therapy'</a> below.)</p><p class="headingAnchor" id="H1207451987"><span class="h2">Hemodynamically stable patients</span><span class="headingEndMark"> — </span>In hemodynamically stable patients, management options include termination of pregnancy (medical or surgical) or continuation of the pregnancy. The optimal management is unclear as there are an insufficient number of reported cases on which to base a specific treatment recommendation. Shared decision-making is essential and guided by factors such as CSP type (see <a class="local">'Classification'</a> above), gestational age, desire for future fertility, and experience of the physician treating the patient.</p><p>Surgical compared with medical therapy may be associated with higher success rates (ie, resolution of the pregnancy). In a systematic review including 3127 patients with CSP (mean gestational age: eight weeks), patients undergoing surgical (ie, hysterectomy, surgical resection, or dilation and curettage [D&amp;C]) compared with medical (ie, intragestational <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> [MTX]) therapy had higher rates of pregnancy resolution (83 versus 60 percent); of the surgical procedures, D&amp;C had the lowest success rates (76 percent) [<a href="#rid52">52</a>]. While rates of hemorrhage were also higher for those managed surgically compared with medically (18 versus 7 percent), use of adjuvant therapies (ie, systemic MTX, UAE) reduced rates of hemorrhage, in most cases. </p><p>Clinicians and patients should consider the following factors when choosing a treatment approach.</p><p class="headingAnchor" id="H2490514270"><span class="h3">Patients with an embryonic/fetal demise</span><span class="headingEndMark"> — </span>CSPs with embryonic/fetal demise may be managed expectantly or with medical or surgical therapy [<a href="#rid25">25,53</a>]. In our practice, we prefer expectant management, especially for those patients in the first trimester, as spontaneous resolution of the pregnancy may occur.</p><p>In the retrospective study described above including patients with CSP diagnosed prior to 14 weeks gestation (see <a class="local">'Natural history'</a> above), 10 patients presented with embryonic demise; seven patients underwent an intervention (ie, ultrasound-guided D&amp;C, intragestational injection of <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">potassium chloride</a> (KCl), systemic MTX, <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a> followed by D&amp;C) and three were expectantly managed [<a href="#rid27">27</a>]. One patient in the intervention group required hysterectomy for bleeding; no patients in the expectant management required hysterectomy.</p><p>For patients choosing expectant management, weekly follow-up with serum human chorionic gonadotropin (hCG) and transvaginal ultrasound (TVUS) are performed until the hCG is undetectable and the pregnancy recedes completely on imaging, which can take several months to occur. </p><p>For patients with incomplete resolution (eg, persistently elevated hCG levels, incomplete resolution on TVUS), or for patients who desire to hasten the resolution of the demised CSP, treatment with systemic MTX or uterine aspiration may be performed (see <a class="local">'Surgical therapy'</a> below and <a class="local">'Medical therapy'</a> below). The diagnosis of embryonic/fetal demise by ultrasonography is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/130879.html" rel="external">"Pregnancy loss (miscarriage): Ultrasound diagnosis"</a>.)</p><p class="headingAnchor" id="H4071906778"><span class="h3">Patients with a live pregnancy</span><span class="headingEndMark"> — </span>Patients with a live CSP may also be managed expectantly or with medical or surgical therapy  (<a class="graphic graphic_algorithm graphicRef134909" href="/z/d/graphic/134909.html" rel="external">algorithm 1</a>). While expectant management of a CSP with a live gestation is associated with severe maternal morbidity (eg, hemorrhage, early uterine rupture, hysterectomy, PAS, maternal death) [<a href="#rid25">25-27,54,55</a>], some patients will deliver a live born neonate at, or near, term (see <a class="local">'Natural history'</a> above); thus, some patients may choose to continue the pregnancy [<a href="#rid53">53</a>]. However, expert groups, including the Society of Maternal-Fetal Medicine, generally advise against this approach [<a href="#rid56">56,57</a>].</p><p class="headingAnchor" id="H635604858"><span class="h4">Expectant management</span><span class="headingEndMark"> — </span>We counsel patients undergoing expectant management that outcomes appear to be more favorable for patients in whom the CSP is "on-the-scar" (type 1) rather than "in-the-niche" (type 2)<strong> and</strong> for those with a myometrial thickness ≥3 mm rather than &lt;3 mm. However, data regarding myometrial thickness vary [<a href="#rid58">58,59</a>], and there is no universally accepted threshold. In one retrospective study including 17 patients with CSP diagnosed prior to nine weeks gestation, patients with "on-the-scar" (type 1) compared with "in-the-niche" (type 2) CSP were delivered at more advanced gestational ages (38 weeks [median; range 37 to 39 weeks] versus 34 weeks [median; range 20 to 36 weeks]) and had lower rates of cesarean-hysterectomy (1 of 6 patients [17 percent] versus 11 of 11 patients [100 percent]) [<a href="#rid1">1</a>]. Myometrial thickness was less in patients requiring cesarean-hysterectomy compared with patients not requiring hysterectomy (1 mm [range 0 to 2 mm] versus 5 mm [range 4 to 9 mm]). While there was a trend towards lower blood loss in patients with "on-the-scar" compared with "in-the-niche" CSP (median: 700 mL versus 1200 mL), this was not statistically significant.</p><p>When expectant management is performed, patients are managed in the same manner as patients with PAS and a repeat cesarean birth is planned between 34 0/7 and 35 6/7 weeks of gestation [<a href="#rid57">57</a>]. This is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/83129.html" rel="external">"Placenta accreta spectrum: Management"</a>.)</p><p class="headingAnchor" id="H1547559658"><span class="h4">Pregnancy termination</span><span class="headingEndMark"> — </span>For patients who choose to terminate their pregnancy (eg, risks outweigh benefits, pregnancy is undesired), treatment is time-sensitive. As with patients without CSP, the morbidity associated with pregnancy termination increases with increasing gestational age. Management (ie, surgical or medical) is effective and depends on the following factors:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Is this a second-trimester CSP?</strong> – For patients in their second trimester, we suggest surgical rather than medical management. In our experience, surgical treatment of second-trimester CSP has a higher success rate than medical treatment. (See <a class="local">'Surgical therapy'</a> below and <a class="local">'Adjunctive therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Is future pregnancy desired? </strong>If future pregnancy is not desired, and for patients who prefer definitive surgical management, gravid hysterectomy may be performed. (See <a class="local">'Surgical therapy'</a> below.)</p><p></p><p class="headingAnchor" id="H852219925"><span class="h2">Specific therapies</span></p><p class="headingAnchor" id="H2748442741"><span class="h3">Surgical therapy</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Operative resection</strong> –Operative resection (eg, wedge resection) of the pregnancy can be performed via laparoscopy [<a href="#rid60">60</a>], hysteroscopy, or (less commonly) laparotomy; laparoscopic-assisted operative hysteroscopic management has also been described [<a href="#rid61">61,62</a>]. Operative resection may also be performed as subsequent management after medical therapy (eg, intragestational injection of MTX or KCl (see <a class="local">'Medical therapy'</a> below)). These procedures should be performed only by highly experienced surgeons.</p><p></p><p class="bulletIndent1">An advantage of resection over other therapies is that the scar can be excised and the uterus reapproximated.</p><p></p><p class="bulletIndent1">Operative resection is also likely to be curative; however, monitoring serum hCG levels weekly until undetectable is reasonable to confirm resolution.</p><p></p><p class="bulletIndent1">The following is a description of a wedge resection performed via laparotomy in a hemodynamically stable patient  (<a class="graphic graphic_movie graphicRef134845" href="/z/d/graphic/134845.html" rel="external">movie 1</a>) [<a href="#rid63">63</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A Pfannenstiel incision is made, and the abdomen entered.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The uterus is grasped with a uterine elevating forceps and delivered through the skin incision.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The peritoneum is incised along the medial aspect of the round ligament; the vesicouterine fold is identified, and both index fingers are used to dissect the posterior bladder from the cervix until the cesarean scar is adequately exposed.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>0-delayed absorbable (Vicryl) suture is placed at the 12, 3 and 9 o'clock positions (and includes the anterior wall of the upper vagina) to occlude the colpo-uterine vessels and reduce blood flow to the CSP.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A scalpel with a number 5 blade is used to cut the uterine tissue around the CSP; approximately 5 mm of healthy myometrial borders are included in the incision.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If bleeding occurs from the sectioned myometrium, 3-0 absorbable suture (rather than electrocautery) is used to obtain hemostasis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The inside of the uterine cavity is wiped with a gauge sponge to remove any remaining pregnancy tissue.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The uterus is closed with 2-0 delayed absorbable suture in a running stitch.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Plasma fibrinogen level is checked; if the level is &lt;200 mg/dL, fibrinogen is replaced. (See  <a class="medical medical_review" href="/z/d/html/1321.html" rel="external">"Disorders of fibrinogen", section on 'Fibrinogen concentrate: Dosing and monitoring'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ultrasound-guided suction aspiration</strong> – Suction aspiration (ie, suction D&amp;C) is typically performed for patients in the early first trimester (five to seven weeks of gestation) with use of a transcervical balloon catheter if heavy bleeding occurs [<a href="#rid64">64,65</a>]. (See <a class="local">'Medical therapy'</a> below.)</p><p></p><p class="bulletIndent1">In one prospective study including 18 cases of CSP (gestational age range: 4 to 23 weeks of gestation), suction curettage was successful in treating five of eight cases (63 percent); three patients (37 percent) experienced significant bleeding (500 to 1000 mL) requiring the insertion of an intrauterine balloon catheter to tamponade the uterine cavity to achieve hemostasis [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gravid hysterectomy</strong> – Gravid hysterectomy should only be performed in patients in whom future childbearing is not desired or in those with life-threatening hemorrhage, and may be the preferred approach for patients with second-trimester CSPs. Gravid hysterectomy may be performed with or without prior UAE. (See <a class="local">'Hemodynamically unstable patients'</a> above and <a class="local">'Adjunctive therapy'</a> below and  <a class="medical medical_review" href="/z/d/html/14194.html" rel="external">"Overview of second-trimester pregnancy termination", section on 'Placental abnormalities'</a>.)</p><p></p><p class="headingAnchor" id="H3850500768"><span class="h3">Medical therapy</span><span class="headingEndMark"> — </span>Medical therapy involves the use of injectable medical agents or local pressure with simple devices such as balloon catheters [<a href="#rid57">57</a>]. These are often office-based procedures and patients may not require hospitalization.</p><p>In our practice, we use systemic MTX as an adjunct to <strong>all</strong> of the following medical therapies; however, there are no high-quality data to support this practice and adverse events can occur. (See <a class="local">'Adjunctive therapy'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intragestational injection of MTX </strong>– Ultrasound-guided (transabdominal or transvaginal) intragestational injection of MTX is an effective treatment for CSP. However, there is insufficient evidence to suggest that this approach is more effective or, conversely, associated with more complications compared with other treatments [<a href="#rid66">66,67</a>].</p><p></p><p class="bulletIndent1">In the prospective study including 18 patients with CSP described above (see <a class="local">'Surgical therapy'</a> above), local injection of 25 mg MTX into the exocoelomic cavity was successful in five of seven cases (71 percent); two of the seven cases (20 percent percent) required emergency surgery to control hemorrhage over 1000 mL [<a href="#rid64">64</a>]. Higher rates of successful resolution have been reported [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent1">A slow resolution of the pregnancy should be expected. In a study of 101 patients with CSP treated with ultrasound-guided MTX injection, the mean time to hCG resolution was 40 days (range 21 to 140 days) [<a href="#rid67">67</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intragestational injection of KCl</strong> – Ultrasound-guided (transabdominal or transvaginal) KCl injection (5 mEq into the gestational sac) into a CSP with embryonic/fetal cardiac activity has also been described [<a href="#rid31">31,68</a>]. This regimen may also be used as a secondary procedure if other treatments (eg, UAE, balloon catheters) do not result in cessation of fetal heart activity. (See  <a class="medical medical_review" href="/z/d/html/6819.html" rel="external">"Induced fetal demise", section on 'Intracardiac potassium chloride injection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transcervical insertion of balloon catheters </strong>– For patients with a CSP ≥6 0/7 and ≤8 6/7 weeks of gestation, balloon catheters are an efficient, safe, well-tolerated, and minimally invasive treatment option [<a href="#rid69">69-71</a>]. In a retrospective study including 18 patients with type 1 CSP, management with a double cervical ripening balloon catheter resulted in successful treatment in all cases; there were no cases of maternal hemorrhage [<a href="#rid69">69</a>]. The majority of patients also received systemic <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>. </p><p></p><p class="bulletIndent1">At later gestational ages (ie, &gt;8 6/7 weeks), cervical ripening balloon catheter use is limited as the pregnancy may be too large to be sufficiently compressed by the balloon.</p><p></p><p class="bulletIndent1">These catheters can effectively stop fetal cardiac activity and prevent possible bleeding complications (by applying direct pressure to the pregnancy), can be used with or without other treatments (eg, uterine aspiration [<a href="#rid64">64,65</a>], intragestational injection of MTX [<a href="#rid69">69</a>] or KCl), and are familiar to obstetricians-gynecologists who use the same cervical ripening catheters for labor induction. In the small retrospective study described above, nine different obstetrician gynecologists performed the procedure without complication and all reported confidence in using this technique [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent1">The various balloon catheters adapted for use in the treatment of CSP include the single Foley balloon catheter [<a href="#rid72">72,73</a>] or the double cervical ripening balloon catheter (ie, double-balloon Cook catheter  (<a class="graphic graphic_picture graphicRef139976" href="/z/d/graphic/139976.html" rel="external">picture 1</a>)) [<a href="#rid65">65,74-77</a>]. These are described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5398.html" rel="external">"Induction of labor: Techniques for preinduction cervical ripening", section on 'Balloon catheter'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The procedure is performed as follows:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Antibiotic prophylaxis: To decrease the risk of infection, antibiotics are routinely administered, although there is no high-quality evidence to support this practice. In our practice we prescribe <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> 500 mg at the time of the procedure, followed by 250 mg daily for four days. However, the optimal dosing regimen has not been established and various other protocol may be used.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Pain control: We administer <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a> 800 mg 30 to 60 minutes prior to the procedure. A paracervical block, using 2 to 3 ml 1% <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a>, is typically performed for patients who have never had a previous vaginal birth or an intrauterine surgical procedure. Intravenous analgesia may also be used for patients requiring additional pain control</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Hegar dilators may be required to achieve an easy passage of the double balloon catheter, which has a slightly larger diameter than a Foley catheter.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Insertion of the catheter and inflation of the intrauterine (anchor) balloon with <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> is performed under transabdominal ultrasound guidance; a small amount of urine in the bladder helps to visualize the advancing catheter. The lower (pressure) balloon is inflated opposite the gestational sac under transvaginal ultrasound guidance  (<a class="graphic graphic_diagnosticimage graphicRef139977" href="/z/d/graphic/139977.html" rel="external">image 7</a>).</p><p></p><p class="bulletIndent3">The amount of fluid used to fill the balloons varies, and <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> is progressively added until the gestational sac collapses.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>At the end of the procedure, the catheter is fastened to the patient's thigh and left in place for 24 to 48 hours. Patients are typically discharged home with instructions on when to return (eg, heavy bleeding, fever, severe pain); inpatient observation may be appropriate for some patients.</p><p></p><p class="bulletIndent1">Before deflating the balloon(s), embryonic/fetal cardiac activity is rechecked to confirm cessation. If cardiac activity is still present, the balloon may be inflated to a higher pressure for an additional 24 to 48 hours; adjuvant therapies (eg, intragestational MTX or KCl, systemic MTX) may be administered, but are rarely required.</p><p></p><p class="bulletIndent1">If cardiac activity has ceased, the balloon catheter is removed; our technique for removal is shown in the following algorithm  (<a class="graphic graphic_algorithm graphicRef140927" href="/z/d/graphic/140927.html" rel="external">algorithm 2</a>). </p><p></p><p class="bulletIndent1">After catheter removal, the patient is closely monitored for any heavy bleeding; the patient should be observed for approximately one hour and can be discharged home with instructions to return for an ultrasound examination within two or three days. Serial ultrasound examinations and hCG levels are typically followed until complete resolution of the CSP.</p><p></p><p class="headingAnchor" id="H1265502038"><span class="h3">Adjunctive therapy</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>UAE </strong>– UAE can be used alone or in combination with other therapies (eg, suction aspiration, MTX, operative hysteroscopy) [<a href="#rid5">5,6,8,11,12,52,57,61,64,78-80</a>]. Patients in whom future fertility is desired should be counseled regarding the risks of pregnancy after UAE, which may be dependent on the embolizing agent(s) used [<a href="#rid80">80,81</a>]. (See  <a class="medical medical_review" href="/z/d/html/3299.html" rel="external">"Uterine fibroids (leiomyomas): Treatment with uterine artery embolization", section on 'Reproductive outcomes'</a>.)</p><p></p><p class="bulletIndent1">UAE may be superior to systemic MTX as an adjunctive treatment to suction curettage [<a href="#rid79">79</a>]. In addition, shorter treatment intervals between UAE and suction aspiration appear to have more favorable outcomes. In a retrospective study including 314 patients with CSP who received UAE followed by suction D&amp;C at time intervals of ≤24, 24 to 48 hours, 48 to 72 hours, and &gt;72 hours, rates of intraoperative hemorrhage ≥200 mL increased (5, 7.8, 10, and 19.4 respectively) as did rates of other complications (6.7, 11.7,15.7, and 25.8 percent, respectively; adjusted odds ratio [OR] at &gt;72 hours: 3.37, 95% CI 1.4-8.09) [<a href="#rid82">82</a>]. Intrauterine balloon tamponade or conversion to emergency laparotomy or laparoscopy occurred in 31 of the 314 patients (10 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic MTX</strong> – We use systemic MTX as an adjunct to all of the above medical therapies; however, there are no high-quality data to support this practice and adverse events (eg, pancytopenia, nephrotoxicity) can occur [<a href="#rid83">83</a>].</p><p></p><p class="bulletIndent1">In the systematic review discussed above (see <a class="local">'Hemodynamically stable patients'</a> above), systemic MTX followed by D&amp;C or surgical (ie, hysteroscopic, laparoscopic) excision was associated with resolution of the pregnancy in 82 and 87 percent of patients, respectively [<a href="#rid52">52</a>]. MTX was typically administered seven days prior to the surgical procedure and resulted in the reduction of blood flow around the scar on Doppler examination and a decline in serum hCG concentrations. Adverse events occurrent in 5 percent of patients and included pelvic infection/fever, elevation of liver enzymes, uterine perforation, and bone marrow suppression.</p><p></p><p class="bulletIndent1">We do <strong>not</strong> use systemic MTX <strong>alone</strong> for the treatment of CSP. This is discussed in detail below. (See <a class="local">'Treatments not used'</a> below.)</p><p></p><p class="headingAnchor" id="H3052180027"><span class="h2">Treatments not used</span><span class="headingEndMark"> — </span>Expert groups recommend <strong>not </strong>using the following treatments:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic MTX alone in patients with a live gestion</strong>– As with ectopic pregnancy, treatment of a pregnancy with fetal cardiac activity with systemic MTX is associated with high rates of treatment failure [<a href="#rid57">57,76,84,85</a>]. Systemic MTX may be used as an adjunct to other treatments and for CSPs with embryonic/fetal demise.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">Misoprostol</a> – While misoprostol may be used for medical termination of first-trimester pregnancies, we do not support its use in treating CSP; the deeply implanted placenta with CSPs appear to prevent the abortive effect of misoprostol, leading to increased rates of treatment failure and severe complications [<a href="#rid85">85,86</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sharp curettage</strong> — Expert groups recommend <strong>against</strong> sharp curettage given the higher risk of complications (eg, perforation, hemorrhage, need for reintervention) [<a href="#rid57">57</a>]; profuse hemorrhage may occur as a result of the deeply implanted placental vessels and scant (or no) myometrium to stop the bleeding vessels severed by sharp curetting. In addition, residual tissue following the D&amp;C may result in subsequent complications, such as enhanced, or extremely enhanced, myometrial vascularity [<a href="#rid29">29,87</a>].</p><p></p><p class="bulletIndent1">While successful termination of CSP has been reported using sharp curettage [<a href="#rid88">88-91</a>], we do not use this approach in our practice.</p><p></p><p class="headingAnchor" id="H4189393194"><span class="h1">FUTURE PREGNANCIES</span><span class="headingEndMark"> — </span>Subsequent pregnancies following CSP have been reported [<a href="#rid32">32,92-95</a>]; such patients are at risk for recurrent scar implantation, abnormal placentation, and uterine rupture (resulting in maternal or fetal death). (See <a class="local">'History of CSP'</a> above.)</p><p class="headingAnchor" id="H293492277"><span class="h2">Role of ultrasound for screening</span><span class="headingEndMark"> — </span>Pregnant patients with a previous cesarean birth and other high-risk patients (eg, history of prior CSP) may benefit from early ultrasound screening in a subsequent pregnancy. In our practice, such patients are counseled to contact their obstetrician gynecologist soon after their positive pregnancy test and undergo a transvaginal ultrasound (TVUS) as early as five to seven weeks of gestation. As this is well before most obstetric practices schedule a first prenatal visit, this requires very early communication between the patient and their physician with swift scheduling of the TVUS. In addition, the ultrasound should be performed by an expert sonologist or physician with experience in diagnosing CSP. Initiation of such measures may not only maximize management options but also may optimize treatment outcomes [<a href="#rid95">95-98</a>].</p><p>Lower severe maternal morbidity (eg, first-trimester hemorrhage, need for blood transfusion, uterine rupture, emergency hysterectomy) has been demonstrated in patients diagnosed and treated at earlier compared with later gestations. In one meta-analysis including 36 studies (724 patients) with CSP and undergoing immediate treatment, those diagnosed ≤9 weeks compared with &gt;9 weeks had lower rates of composite adverse maternal outcomes (5.9 versus 32.4 percent, odds ratio [OR] 0.14, 95 % CI 0.1-0.4) [<a href="#rid95">95</a>]. Future studies are needed to assess the cost-effectiveness of such measures [<a href="#rid97">97</a>].</p><p class="headingAnchor" id="H3637894840"><span class="h1">REGISTRY</span><span class="headingEndMark"> — </span>An international CSP registry has been established to better understand the disease [<a href="#rid99">99</a>]. Information is available <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fcsp-registry.com%2F&amp;token=lqPI6Mnc3gqBEh%2FkWA22cf1V6f60mBVo78dbKmxG%2BW6IuiYiyCp0aYIgzSi%2F5x8c&amp;TOPIC_ID=131912" target="_blank">online</a>.</p><p class="headingAnchor" id="H474190903"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118733.html" rel="external">"Society guideline links: Obstetric hemorrhage"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/118506.html" rel="external">"Society guideline links: Ectopic pregnancy"</a>.)</p><p class="headingAnchor" id="H3850662006"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Terminology</strong> – Cesarean scar pregnancy (CSP) refers to a pregnancy that is implanted on ("on-the-scar" [type 1]) or in ("in-the-niche" [type 2]) a scar from a prior cesarean birth (or rarely from a prior myomectomy). If unrecognized or inadequately managed, CSP can lead to severe maternal and fetal outcomes (eg, uterine rupture, hemorrhage, death). (See <a class="local">'Introduction'</a> above and <a class="local">'Classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – CSP is a likely a precursor to, and shares a common histology with, placenta accreta spectrum (PAS). The two are likely a continuum of the same disease. (See <a class="local">'Pathogenesis'</a> above and  <a class="medical medical_review" href="/z/d/html/6759.html" rel="external">"Placenta accreta spectrum: Clinical features, diagnosis, and potential consequences"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Natural history</strong> – CSPs are associated with high maternal and fetal morbidity (eg, hemorrhage, uterine rupture, PAS) and even mortality. However, some CSPs may continue to a viable gestation. Clinical outcomes appear to be more favorable for "on-the-scar" versus "in-the-niche" CSPs; however, data are limited as CSP type is often not specified in ultrasound reports or published studies. (See <a class="local">'Natural history'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>CSP is a diagnosis made based on first- (or early second-) trimester transvaginal ultrasound (TVUS) findings of a pregnancy implanted on or in a prior hysterotomy scar/niche and confirmed at the time of surgery with histologic findings consistent with PAS disorder. (See <a class="local">'Definitive diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other early ultrasound findings suggestive of CSP in a patient with a prior uterine scar include a low anterior position of the gestational sac at ≤7 weeks; low-lying anterior placenta or placenta previa; placental lacunae; thin (&lt;3 mm) or no intervening myometrium/clear space (ie, residual myometrial thickness) between the placenta and bladder or anterior uterine serosa; irregular or disrupted bladder line or anteriorly bulging sac into the bladder; and increased vascularity at the bladder/placental interphase. (See <a class="local">'Findings suggestive of the diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – All patients with CSP should be transferred, whenever possible, to a center of excellence for PAS, or a tertiary care hospital in which maternal-fetal medicine specialists, a variety of treatment options (eg, uterine artery embolization [UAE]), and blood bank services are available. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A patient with hemorrhage and existing or impending hemodynamic instability requires immediate surgical intervention (eg, wedge resection, gravid hysterectomy) and/or a minimally invasive procedure (ie, UAE). (See <a class="local">'Hemodynamically unstable patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For hemodynamically stable patients, the optimal management (ie, surgical or medical termination, expectant management) is unclear. While expert groups generally advise pregnancy termination, some pregnancies will continue to, or close to, term and thus some patients will choose to continue the pregnancy. Shared decision-making is essential and guided by factors such as CSP type, gestational age, desire for future fertility, and experience of the physician treating the patient. (See <a class="local">'Hemodynamically stable patients'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients with an embryonic/fetal demise can be managed expectantly or with medical or surgical therapy. (See <a class="local">'Patients with an embryonic/fetal demise'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with a desired, live pregnancy, outcomes appear to be more favorable for patients in whom the CSP is "on-the-scar" (type 1)<strong> and</strong> with a myometrial thickness ≥3 mm  (<a class="graphic graphic_algorithm graphicRef134909" href="/z/d/graphic/134909.html" rel="external">algorithm 1</a>). Thus, we offer expectant management to such patients and manage similarly to patients with PAS. Outcomes appear to be less favorable for patients in whom the CSP is "in-the-niche" (type 2) or with a myometrial thickness &lt;3 mm. (See <a class="local">'Expectant management'</a> above and  <a class="medical medical_review" href="/z/d/html/83129.html" rel="external">"Placenta accreta spectrum: Management"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with a live pregnancy choosing termination at more advanced (ie, second trimester) gestational ages, we suggest surgical rather than medical therapies  (<a class="graphic graphic_algorithm graphicRef134909" href="/z/d/graphic/134909.html" rel="external">algorithm 1</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For patients at earlier gestations, medical or surgical therapies can be used. (See <a class="local">'Pregnancy termination'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>UAE and systemic <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (MTX) are frequently used as adjunctive therapy to both medical and surgical treatments; patients should be counseled regarding the benefits and risks of such treatment. (See <a class="local">'Adjunctive therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We do <strong>not</strong> use of systemic MTX alone, <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a>, or sharp uterine curettage for the management of CSP. (See <a class="local">'Treatments not used'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening</strong> – Pregnant patients with a prior cesarean birth and other risk factors for CSP (eg, prior CSP) may benefit from early (ie, five to seven weeks of gestation) ultrasound screening to determine if abnormal implantation has occurred. (See <a class="local">'Role of ultrasound for screening'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kaelin Agten A, Cali G, Monteagudo A, et al. The clinical outcome of cesarean scar pregnancies implanted "on the scar" versus "in the niche". Am J Obstet Gynecol 2017; 216:510.e1.</a></li><li><a class="nounderline abstract_t">Ban Y, Shen J, Wang X, et al. Cesarean Scar Ectopic Pregnancy Clinical Classification System With Recommended Surgical Strategy. Obstet Gynecol 2023; 141:927.</a></li><li><a class="nounderline abstract_t">Lin SY, Hsieh CJ, Tu YA, et al. New ultrasound grading system for cesarean scar pregnancy and its implications for management strategies: An observational cohort study. PLoS One 2018; 13:e0202020.</a></li><li><a class="nounderline abstract_t">Lee CL, Wang CJ, Chao A, et al. Laparoscopic management of an ectopic pregnancy in a previous Caesarean section scar. Hum Reprod 1999; 14:1234.</a></li><li><a class="nounderline abstract_t">Valley MT, Pierce JG, Daniel TB, Kaunitz AM. Cesarean scar pregnancy: imaging and treatment with conservative surgery. Obstet Gynecol 1998; 91:838.</a></li><li><a class="nounderline abstract_t">Rotas MA, Haberman S, Levgur M. Cesarean scar ectopic pregnancies: etiology, diagnosis, and management. Obstet Gynecol 2006; 107:1373.</a></li><li><a class="nounderline abstract_t">Ko JK, Li RH, Cheung VY. Caesarean scar pregnancy: a 10-year experience. Aust N Z J Obstet Gynaecol 2015; 55:64.</a></li><li><a class="nounderline abstract_t">Wong KS, Tan J, Ang C, Ngu A. Myomectomy scar ectopic pregnancy. Aust N Z J Obstet Gynaecol 2010; 50:93.</a></li><li><a class="nounderline abstract_t">Toro-Bejarano M, Mora R, Timor-Tristch IE, et al. Myomectomy scar pregnancy ‒ a serious, but scarcely reported entity: literature review and an instructive case. J Perinat Med 2021; 10:20210071.</a></li><li><a class="nounderline abstract_t">Hsieh BC, Hwang JL, Pan HS, et al. Heterotopic Caesarean scar pregnancy combined with intrauterine pregnancy successfully treated with embryo aspiration for selective embryo reduction: case report. Hum Reprod 2004; 19:285.</a></li><li><a class="nounderline abstract_t">Marchiolé P, Gorlero F, de Caro G, et al. Intramural pregnancy embedded in a previous Cesarean section scar treated conservatively. Ultrasound Obstet Gynecol 2004; 23:307.</a></li><li><a class="nounderline abstract_t">Ash A, Smith A, Maxwell D. Caesarean scar pregnancy. BJOG 2007; 114:253.</a></li><li><a class="nounderline abstract_t">Tantbirojn P, Crum CP, Parast MM. Pathophysiology of placenta creta: the role of decidua and extravillous trophoblast. Placenta 2008; 29:639.</a></li><li><a class="nounderline abstract_t">Jauniaux E, Jurkovic D. Placenta accreta: pathogenesis of a 20th century iatrogenic uterine disease. Placenta 2012; 33:244.</a></li><li class="breakAll">Jauniaux E. Pathophysiology and ultrasound imaging of placenta accreta spectrum. Am J Obstet Gynecol 2018.</li><li><a class="nounderline abstract_t">Genbacev O, Miller RK. Post-implantation differentiation and proliferation of cytotrophoblast cells: in vitro models--a review. Placenta 2000; 21 Suppl A:S45.</a></li><li><a class="nounderline abstract_t">Timor-Tritsch IE, Monteagudo A, Cali G, et al. Cesarean scar pregnancy is a precursor of morbidly adherent placenta. Ultrasound Obstet Gynecol 2014; 44:346.</a></li><li><a class="nounderline abstract_t">Timor-Tritsch IE, Monteagudo A, Cali G, et al. Cesarean scar pregnancy and early placenta accreta share common histology. Ultrasound Obstet Gynecol 2014; 43:383.</a></li><li><a class="nounderline abstract_t">Jauniaux E, Jurkovic D, Hussein AM, Burton GJ. New insights into the etiopathology of placenta accreta spectrum. Am J Obstet Gynecol 2022; 227:384.</a></li><li><a class="nounderline abstract_t">Comstock CH, Bronsteen RA. The antenatal diagnosis of placenta accreta. BJOG 2014; 121:171.</a></li><li><a class="nounderline abstract_t">Ballas J, Pretorius D, Hull AD, et al. Identifying sonographic markers for placenta accreta in the first trimester. J Ultrasound Med 2012; 31:1835.</a></li><li><a class="nounderline abstract_t">Rac MW, Moschos E, Wells CE, et al. Sonographic Findings of Morbidly Adherent Placenta in the First Trimester. J Ultrasound Med 2016; 35:263.</a></li><li><a class="nounderline abstract_t">D'Antonio F, Timor-Tritsch IE, Palacios-Jaraquemada J, et al. First-trimester detection of abnormally invasive placenta in high-risk women: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2018; 51:176.</a></li><li><a class="nounderline abstract_t">Suzuki N, Kyozuka H, Fukuda T, et al. Late-diagnosed cesarean scar pregnancy resulting in unexpected placenta accreta spectrum necessitating hysterectomy. Fukushima J Med Sci 2020; 66:156.</a></li><li><a class="nounderline abstract_t">Calì G, Timor-Tritsch IE, Palacios-Jaraquemada J, et al. Outcome of Cesarean scar pregnancy managed expectantly: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2018; 51:169.</a></li><li><a class="nounderline abstract_t">Zosmer N, Fuller J, Shaikh H, et al. Natural history of early first-trimester pregnancies implanted in Cesarean scars. Ultrasound Obstet Gynecol 2015; 46:367.</a></li><li><a class="nounderline abstract_t">Michaels AY, Washburn EE, Pocius KD, et al. Outcome of cesarean scar pregnancies diagnosed sonographically in the first trimester. J Ultrasound Med 2015; 34:595.</a></li><li><a class="nounderline abstract_t">Timor-Tritsch IE, Haynes MC, Monteagudo A, et al. Ultrasound diagnosis and management of acquired uterine enhanced myometrial vascularity/arteriovenous malformations. Am J Obstet Gynecol 2016; 214:731.e1.</a></li><li><a class="nounderline abstract_t">Timor-Tritsch IE, McDermott WM, Monteagudo A, et al. Extreme enhanced myometrial vascularity following cesarean scar pregnancy: a new diagnostic entity. J Matern Fetal Neonatal Med 2022; 35:5846.</a></li><li><a class="nounderline abstract_t">Kaelin Agten A, Ringel N, Ramos J, et al. Standardization of peak systolic velocity measurement in enhanced myometrial vascularity. Am J Obstet Gynecol 2016; 215:802.</a></li><li><a class="nounderline abstract_t">Timor-Tritsch IE, Khatib N, Monteagudo A, et al. Cesarean scar pregnancies: experience of 60 cases. J Ultrasound Med 2015; 34:601.</a></li><li><a class="nounderline abstract_t">Morlando M, Buca D, Timor-Tritsch I, et al. Reproductive outcome after cesarean scar pregnancy: A systematic review and meta-analysis. Acta Obstet Gynecol Scand 2020; 99:1278.</a></li><li><a class="nounderline abstract_t">Timor-Tritsch IE, Horwitz G, D'Antonio F, et al. Recurrent Cesarean scar pregnancy: case series and literature review. Ultrasound Obstet Gynecol 2021; 58:121.</a></li><li><a class="nounderline abstract_t">Vial Y, Petignat P, Hohlfeld P. Pregnancy in a cesarean scar. Ultrasound Obstet Gynecol 2000; 16:592.</a></li><li><a class="nounderline abstract_t">Gonzalez N, Tulandi T. Cesarean Scar Pregnancy: A Systematic Review. J Minim Invasive Gynecol 2017; 24:731.</a></li><li><a class="nounderline abstract_t">Hilal K, Masroor I, Aziz A, Sayani R. Acquired vascular malformation in ruptured caesarean section scar: a rare cause of life-threatening vaginal bleeding. BMJ Case Rep 2013; 2013.</a></li><li><a class="nounderline abstract_t">Liu G, Shang X, Qi Z, Xue F. Large intrauterine mass associated with cesarean scar pregnancy. Am J Obstet Gynecol 2016; 214:126.e1.</a></li><li><a class="nounderline abstract_t">Berhie SH, Molina RL, Davis MR, et al. Beware the scar: Laparoscopic hysterectomy for 7-week cesarean delivery scar implantation pregnancy. Am J Obstet Gynecol 2015; 212:247.e1.</a></li><li><a class="nounderline abstract_t">Riaz RM, Williams TR, Craig BM, Myers DT. Cesarean scar ectopic pregnancy: imaging features, current treatment options, and clinical outcomes. Abdom Imaging 2015; 40:2589.</a></li><li><a class="nounderline abstract_t">Timor-Tritsch IE, Monteagudo A, Calì G, et al. Hidden in plain sight: role of residual myometrial thickness to predict outcome of Cesarean scar pregnancy. Ultrasound Obstet Gynecol 2023; 62:624.</a></li><li><a class="nounderline abstract_t">Timor-Tritsch IE, Monteagudo A, Cali G, et al. Easy sonographic differential diagnosis between intrauterine pregnancy and cesarean delivery scar pregnancy in the early first trimester. Am J Obstet Gynecol 2016; 215:225.e1.</a></li><li><a class="nounderline abstract_t">Happe SK, Rac MWF, Moschos E, et al. Prospective First-Trimester Ultrasound Imaging of Low Implantation and Placenta Accreta Spectrum. J Ultrasound Med 2020; 39:1907.</a></li><li><a class="nounderline abstract_t">Jauniaux E, Zosmer N, De Braud LV, et al. Development of the utero-placental circulation in cesarean scar pregnancies: a case-control study. Am J Obstet Gynecol 2022; 226:399.e1.</a></li><li><a class="nounderline abstract_t">Cali G, Forlani F, Timor-Trisch I, et al. Diagnostic accuracy of ultrasound in detecting the depth of invasion in women at risk of abnormally invasive placenta: A prospective longitudinal study. Acta Obstet Gynecol Scand 2018; 97:1219.</a></li><li><a class="nounderline abstract_t">Calì G, D'Antonio F, Forlani F, et al. Ultrasound Detection of Bladder-Uterovaginal Anastomoses in Morbidly Adherent Placenta. Fetal Diagn Ther 2017; 41:239.</a></li><li><a class="nounderline abstract_t">Calì G, Timor-Trisch IE, Palacios-Jaraquemada J, et al. Changes in ultrasonography indicators of abnormally invasive placenta during pregnancy. Int J Gynaecol Obstet 2018; 140:319.</a></li><li><a class="nounderline abstract_t">Cali G, Forlani F, Timor-Tritsch IE, et al. Natural history of Cesarean scar pregnancy on prenatal ultrasound: the crossover sign. Ultrasound Obstet Gynecol 2017; 50:100.</a></li><li><a class="nounderline abstract_t">Lee SR, Park SY, Park MH. Cesarean scar pregnancy associated with an impending uterine rupture diagnosed with 3-dimensional ultrasonography. Am J Obstet Gynecol 2017; 216:531.e1.</a></li><li><a class="nounderline abstract_t">Shih JC. Cesarean scar pregnancy: diagnosis with three-dimensional (3D) ultrasound and 3D power Doppler. Ultrasound Obstet Gynecol 2004; 23:306.</a></li><li><a class="nounderline abstract_t">Jordans IPM, Verberkt C, De Leeuw RA, et al. Definition and sonographic reporting system for Cesarean scar pregnancy in early gestation: modified Delphi method. Ultrasound Obstet Gynecol 2022; 59:437.</a></li><li><a class="nounderline abstract_t">Timor-Tritsch IE, Monteagudo A. Unforeseen consequences of the increasing rate of cesarean deliveries: early placenta accreta and cesarean scar pregnancy. A review. Am J Obstet Gynecol 2012; 207:14.</a></li><li><a class="nounderline abstract_t">Maheux-Lacroix S, Li F, Bujold E, et al. Cesarean Scar Pregnancies: A Systematic Review of Treatment Options. J Minim Invasive Gynecol 2017; 24:915.</a></li><li><a class="nounderline abstract_t">Timor-Tritsch IE, Monteagudo A, Calì G, et al. Cesarean Scar Pregnancy: Patient Counseling and Management. Obstet Gynecol Clin North Am 2019; 46:813.</a></li><li><a class="nounderline abstract_t">Ben Nagi J, Ofili-Yebovi D, Marsh M, Jurkovic D. First-trimester cesarean scar pregnancy evolving into placenta previa/accreta at term. J Ultrasound Med 2005; 24:1569.</a></li><li><a class="nounderline abstract_t">Calì G, Forlani F, Minneci G, et al. First-trimester prediction of surgical outcome in abnormally invasive placenta using the cross-over sign. Ultrasound Obstet Gynecol 2018; 51:184.</a></li><li><a class="nounderline abstract_t">He F, Li JQ, Tang XL, et al. [Expectant management of 11 cases of cesarean scar pregnancy]. Zhonghua Fu Chan Ke Za Zhi 2017; 52:594.</a></li><li><a class="nounderline abstract_t">Society for Maternal-Fetal Medicine (SMFM), Miller R, Gyamfi-Bannerman C, Publications Committee. Electronic address: <span class="__cf_email__" data-cfemail="6e1e1b0c1d2e1d03080340011c09">[email protected]</span>. Society for Maternal-Fetal Medicine Consult Series #63: Cesarean scar ectopic pregnancy. Am J Obstet Gynecol 2022; 227:B9.</a></li><li><a class="nounderline abstract_t">Karakuş R, Karakuş SS, Güler B, et al. Myometrial thickness overlying cesarean scar pregnancy is significantly associated with isthmocele formation in the third month of the postoperative period. Turk J Obstet Gynecol 2021; 18:37.</a></li><li><a class="nounderline abstract_t">Twickler DM, Lucas MJ, Balis AB, et al. Color flow mapping for myometrial invasion in women with a prior cesarean delivery. J Matern Fetal Med 2000; 9:330.</a></li><li><a class="nounderline abstract_t">Pickett CM, Minalt N, Higgins OM, et al. A laparoscopic approach to cesarean scar ectopic pregnancy. Am J Obstet Gynecol 2022; 226:417.</a></li><li><a class="nounderline abstract_t">Robinson JK, Dayal MB, Gindoff P, Frankfurter D. A novel surgical treatment for cesarean scar pregnancy: laparoscopically assisted operative hysteroscopy. Fertil Steril 2009; 92:1497.e13.</a></li><li><a class="nounderline abstract_t">Zhang X, Pang Y, Ma Y, et al. A comparison between laparoscopy and hysteroscopy approach in treatment of cesarean scar pregnancy. Medicine (Baltimore) 2020; 99:e22845.</a></li><li class="breakAll">Personal communication on 10/22/2021 with José Palacios-Jaraquemada, MD, PhD.</li><li><a class="nounderline abstract_t">Jurkovic D, Hillaby K, Woelfer B, et al. First-trimester diagnosis and management of pregnancies implanted into the lower uterine segment Cesarean section scar. Ultrasound Obstet Gynecol 2003; 21:220.</a></li><li><a class="nounderline abstract_t">Wu C, Li Y, Ye W, et al. Cook Cervical Ripening Balloon successfully prevents excessive hemorrhage combined with ultrasound-guided suction curettage in the treatment of cesarean scar pregnancy. J Obstet Gynaecol Res 2017; 43:1043.</a></li><li><a class="nounderline abstract_t">Timor-Tritsch IE, Monteagudo A, Santos R, et al. The diagnosis, treatment, and follow-up of cesarean scar pregnancy. Am J Obstet Gynecol 2012; 207:44.e1.</a></li><li><a class="nounderline abstract_t">Li Q, Xu H, Wang Y, et al. Ultrasound-guided local methotrexate treatment for cesarean scar pregnancy in the first trimester: 12 years of single-center experience in China. Eur J Obstet Gynecol Reprod Biol 2019; 243:162.</a></li><li><a class="nounderline abstract_t">Salomon LJ, Fernandez H, Chauveaud A, et al. Successful management of a heterotopic Caesarean scar pregnancy: potassium chloride injection with preservation of the intrauterine gestation: case report. Hum Reprod 2003; 18:189.</a></li><li><a class="nounderline abstract_t">Kus LH, Veade AE, Eisenberg DL, et al. Maternal Morbidity After Double Balloon Catheter Management of Cesarean Scar and Cervical Pregnancies. Obstet Gynecol 2022; 140:993.</a></li><li><a class="nounderline abstract_t">Spazzini MD, Villa A, Maffioletti C, et al. First-trimester treatment of cesarean scar pregnancy using a cervical ripening-double-balloon catheter: A case report. J Clin Ultrasound 2020; 48:298.</a></li><li><a class="nounderline abstract_t">Grechukhina O, Deshmukh U, Fan L, et al. Cesarean Scar Pregnancy, Incidence, and Recurrence: Five-Year Experience at a Single Tertiary Care Referral Center. Obstet Gynecol 2018; 132:1285.</a></li><li><a class="nounderline abstract_t">Jiang T, Liu G, Huang L, et al. Methotrexate therapy followed by suction curettage followed by Foley tamponade for caesarean scar pregnancy. Eur J Obstet Gynecol Reprod Biol 2011; 156:209.</a></li><li><a class="nounderline abstract_t">Timor-Tritsch IE, Cali G, Monteagudo A, et al. Foley balloon catheter to prevent or manage bleeding during treatment for cervical and Cesarean scar pregnancy. Ultrasound Obstet Gynecol 2015; 46:118.</a></li><li><a class="nounderline abstract_t">Timor-Tritsch IE, Monteagudo A, Kaelin Agten A. Recap-Minimally invasive treatment for cesarean scar pregnancy using a double-balloon catheter: additional suggestions to the technique. Am J Obstet Gynecol 2017; 217:496.</a></li><li><a class="nounderline abstract_t">Monteagudo A, Calì G, Rebarber A, et al. Minimally Invasive Treatment of Cesarean Scar and Cervical Pregnancies Using a Cervical Ripening Double Balloon Catheter: Expanding the Clinical Series. J Ultrasound Med 2019; 38:785.</a></li><li><a class="nounderline abstract_t">Lam PM, Lo KW, Lau TK. Unsuccessful medical treatment of cesarean scar ectopic pregnancy with systemic methotrexate: a report of two cases. Acta Obstet Gynecol Scand 2004; 83:108.</a></li><li><a class="nounderline abstract_t">Timor-Tritsch IE, Monteagudo A, Bennett TA, et al. A new minimally invasive treatment for cesarean scar pregnancy and cervical pregnancy. Am J Obstet Gynecol 2016; 215:351.e1.</a></li><li><a class="nounderline abstract_t">Birch Petersen K, Hoffmann E, Rifbjerg Larsen C, Svarre Nielsen H. Cesarean scar pregnancy: a systematic review of treatment studies. Fertil Steril 2016; 105:958.</a></li><li><a class="nounderline abstract_t">Zhuang Y, Huang L. Uterine artery embolization compared with methotrexate for the management of pregnancy implanted within a cesarean scar. Am J Obstet Gynecol 2009; 201:152.e1.</a></li><li><a class="nounderline abstract_t">Toguchi M, Iraha Y, Ito J, et al. Uterine artery embolization for postpartum and postabortion hemorrhage: a retrospective analysis of complications, subsequent fertility and pregnancy outcomes. Jpn J Radiol 2020; 38:240.</a></li><li><a class="nounderline abstract_t">Zhang XQ, Chen XT, Zhang YT, Mai CX. The Emergent Pelvic Artery Embolization in the Management of Postpartum Hemorrhage: A Systematic Review and Meta-analysis. Obstet Gynecol Surv 2021; 76:234.</a></li><li><a class="nounderline abstract_t">Wang Q, Peng H, Zhao X, Qi X. When to perform curettage after uterine artery embolization for cesarean scar pregnancy: a clinical study. BMC Pregnancy Childbirth 2021; 21:367.</a></li><li><a class="nounderline abstract_t">Collins SL, Alemdar B, van Beekhuizen HJ, et al. Evidence-based guidelines for the management of abnormally invasive placenta: recommendations from the International Society for Abnormally Invasive Placenta. Am J Obstet Gynecol 2019; 220:511.</a></li><li><a class="nounderline abstract_t">Pirtea L, Balint O, Secosan C, et al. Laparoscopic Resection of Cesarean Scar Ectopic Pregnancy after Unsuccessful Systemic Methotrexate Treatment. J Minim Invasive Gynecol 2019; 26:399.</a></li><li><a class="nounderline abstract_t">Lin CH, Yu MH, Chang FW. Cervical priming with misoprostol for the termination of cesarean scar pregnancy. Taiwan J Obstet Gynecol 2014; 53:109.</a></li><li><a class="nounderline abstract_t">Rouzi AA, Almarzouki A, Tallab F, Ashkar L. Medical management of early pregnancy failure with misoprostol with rupture of the cesarean section scar pregnancy. Clin Exp Obstet Gynecol 2017; 44:477.</a></li><li><a class="nounderline abstract_t">Qian ZD, Weng Y, Du YJ, et al. Management of persistent caesarean scar pregnancy after curettage treatment failure. BMC Pregnancy Childbirth 2017; 17:208.</a></li><li><a class="nounderline abstract_t">Jurkovic D, Knez J, Appiah A, et al. Surgical treatment of Cesarean scar ectopic pregnancy: efficacy and safety of ultrasound-guided suction curettage. Ultrasound Obstet Gynecol 2016; 47:511.</a></li><li><a class="nounderline abstract_t">Zhang Y, Chen L, Zhou M, et al. Risk factors of persistent cesarean scar pregnancy after dilation and curettage: a matched case-control study. Taiwan J Obstet Gynecol 2020; 59:237.</a></li><li><a class="nounderline abstract_t">Liu S, Sun J, Cai B, et al. Management of Cesarean Scar Pregnancy Using Ultrasound-Guided Dilation and Curettage. J Minim Invasive Gynecol 2016; 23:707.</a></li><li><a class="nounderline abstract_t">Sugawara J, Senoo M, Chisaka H, et al. Successful conservative treatment of a cesarean scar pregnancy with uterine artery embolization. Tohoku J Exp Med 2005; 206:261.</a></li><li><a class="nounderline abstract_t">Ben Nagi J, Helmy S, Ofili-Yebovi D, et al. Reproductive outcomes of women with a previous history of Caesarean scar ectopic pregnancies. Hum Reprod 2007; 22:2012.</a></li><li><a class="nounderline abstract_t">Seow KM, Huang LW, Lin YH, et al. Cesarean scar pregnancy: issues in management. Ultrasound Obstet Gynecol 2004; 23:247.</a></li><li><a class="nounderline abstract_t">Seow KM, Hwang JL, Tsai YL, et al. Subsequent pregnancy outcome after conservative treatment of a previous cesarean scar pregnancy. Acta Obstet Gynecol Scand 2004; 83:1167.</a></li><li><a class="nounderline abstract_t">Timor-Tritsch I, Buca D, Di Mascio D, et al. Outcome of cesarean scar pregnancy according to gestational age at diagnosis: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2021; 258:53.</a></li><li><a class="nounderline abstract_t">Calí G, Timor-Tritsch IE, Forlani F, et al. Value of first-trimester ultrasound in prediction of third-trimester sonographic stage of placenta accreta spectrum disorder and surgical outcome. Ultrasound Obstet Gynecol 2020; 55:450.</a></li><li><a class="nounderline abstract_t">Rosen T. Placenta accreta and cesarean scar pregnancy: overlooked costs of the rising cesarean section rate. Clin Perinatol 2008; 35:519.</a></li><li><a class="nounderline abstract_t">Timor-Tritsch IE, D'Antonio F, Calí G, et al. Early first-trimester transvaginal ultrasound is indicated in pregnancy after previous Cesarean delivery: should it be mandatory? Ultrasound Obstet Gynecol 2019; 54:156.</a></li><li><a class="nounderline abstract_t">Agten AK, Monteagudo A, Timor-Tritsch IE, Thilaganathan B. Cesarean Scar Pregnancy Registry: an international research platform. Ultrasound Obstet Gynecol 2020; 55:438.</a></li></ol></div><div id="topicVersionRevision">Topic 131912 Version 14.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28115056" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The clinical outcome of cesarean scar pregnancies implanted "on the scar" versus "in the niche".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37023450" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cesarean Scar Ectopic Pregnancy Clinical Classification System With Recommended Surgical Strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30092014" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : New ultrasound grading system for cesarean scar pregnancy and its implications for management strategies: An observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10325269" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Laparoscopic management of an ectopic pregnancy in a previous Caesarean section scar.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9572183" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cesarean scar pregnancy: imaging and treatment with conservative surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16738166" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cesarean scar ectopic pregnancies: etiology, diagnosis, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25350856" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Caesarean scar pregnancy: a 10-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20219005" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Myomectomy scar ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Myomectomy scar pregnancy‒a serious, but scarcely reported entity: literature review and an instructive case</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14747168" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Heterotopic Caesarean scar pregnancy combined with intrauterine pregnancy successfully treated with embryo aspiration for selective embryo reduction: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15027026" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Intramural pregnancy embedded in a previous Cesarean section scar treated conservatively.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17313383" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Caesarean scar pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18514815" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pathophysiology of placenta creta: the role of decidua and extravillous trophoblast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22284667" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Placenta accreta: pathogenesis of a 20th century iatrogenic uterine disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22284667" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Placenta accreta: pathogenesis of a 20th century iatrogenic uterine disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10831121" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Post-implantation differentiation and proliferation of cytotrophoblast cells: in vitro models--a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24890256" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cesarean scar pregnancy is a precursor of morbidly adherent placenta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24357257" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cesarean scar pregnancy and early placenta accreta share common histology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35248577" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : New insights into the etiopathology of placenta accreta spectrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24373591" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The antenatal diagnosis of placenta accreta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23091257" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Identifying sonographic markers for placenta accreta in the first trimester.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26657748" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Sonographic Findings of Morbidly Adherent Placenta in the First Trimester.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28833750" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : First-trimester detection of abnormally invasive placenta in high-risk women: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32981904" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Late-diagnosed cesarean scar pregnancy resulting in unexpected placenta accreta spectrum necessitating hysterectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28661021" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Outcome of Cesarean scar pregnancy managed expectantly: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25586877" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Natural history of early first-trimester pregnancies implanted in Cesarean scars.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25792574" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Outcome of cesarean scar pregnancies diagnosed sonographically in the first trimester.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26873276" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Ultrasound diagnosis and management of acquired uterine enhanced myometrial vascularity/arteriovenous malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33730990" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Extreme enhanced myometrial vascularity following cesarean scar pregnancy: a new diagnostic entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27544329" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Standardization of peak systolic velocity measurement in enhanced myometrial vascularity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25792575" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Cesarean scar pregnancies: experience of 60 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32419158" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Reproductive outcome after cesarean scar pregnancy: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33411387" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Recurrent Cesarean scar pregnancy: case series and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11169360" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Pregnancy in a cesarean scar.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28268103" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cesarean Scar Pregnancy: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23839607" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Acquired vascular malformation in ruptured caesarean section scar: a rare cause of life-threatening vaginal bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26342898" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Large intrauterine mass associated with cesarean scar pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25448514" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Beware the scar: Laparoscopic hysterectomy for 7-week cesarean delivery scar implantation pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26070747" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cesarean scar ectopic pregnancy: imaging features, current treatment options, and clinical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37266902" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Hidden in plain sight: role of residual myometrial thickness to predict outcome of Cesarean scar pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26899908" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Easy sonographic differential diagnosis between intrauterine pregnancy and cesarean delivery scar pregnancy in the early first trimester.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32374433" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Prospective First-Trimester Ultrasound Imaging of Low Implantation and Placenta Accreta Spectrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34492222" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Development of the utero-placental circulation in cesarean scar pregnancies: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29797715" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Diagnostic accuracy of ultrasound in detecting the depth of invasion in women at risk of abnormally invasive placenta: A prospective longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27160715" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Ultrasound Detection of Bladder-Uterovaginal Anastomoses in Morbidly Adherent Placenta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29197083" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Changes in ultrasonography indicators of abnormally invasive placenta during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27420402" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Natural history of Cesarean scar pregnancy on prenatal ultrasound: the crossover sign.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28216059" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Cesarean scar pregnancy associated with an impending uterine rupture diagnosed with 3-dimensional ultrasonography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15027025" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Cesarean scar pregnancy: diagnosis with three-dimensional (3D) ultrasound and 3D power Doppler.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34779085" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Definition and sonographic reporting system for Cesarean scar pregnancy in early gestation: modified Delphi method.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22516620" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Unforeseen consequences of the increasing rate of cesarean deliveries: early placenta accreta and cesarean scar pregnancy. A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28599886" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Cesarean Scar Pregnancies: A Systematic Review of Treatment Options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31677756" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cesarean Scar Pregnancy: Patient Counseling and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16239664" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : First-trimester cesarean scar pregnancy evolving into placenta previa/accreta at term.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28233462" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : First-trimester prediction of surgical outcome in abnormally invasive placenta using the cross-over sign.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28954447" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : [Expectant management of 11 cases of cesarean scar pregnancy].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35850938" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Society for Maternal-Fetal Medicine Consult Series #63: Cesarean scar ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33715331" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Myometrial thickness overlying cesarean scar pregnancy is significantly associated with isthmocele formation in the third month of the postoperative period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11243289" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Color flow mapping for myometrial invasion in women with a prior cesarean delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34774522" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A laparoscopic approach to cesarean scar ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19683711" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A novel surgical treatment for cesarean scar pregnancy: laparoscopically assisted operative hysteroscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33120815" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A comparison between laparoscopy and hysteroscopy approach in treatment of cesarean scar pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33120815" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A comparison between laparoscopy and hysteroscopy approach in treatment of cesarean scar pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12666214" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : First-trimester diagnosis and management of pregnancies implanted into the lower uterine segment Cesarean section scar.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28498646" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Cook Cervical Ripening Balloon successfully prevents excessive hemorrhage combined with ultrasound-guided suction curettage in the treatment of cesarean scar pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22607667" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The diagnosis, treatment, and follow-up of cesarean scar pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31706056" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Ultrasound-guided local methotrexate treatment for cesarean scar pregnancy in the first trimester: 12 years of single-center experience in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12525465" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Successful management of a heterotopic Caesarean scar pregnancy: potassium chloride injection with preservation of the intrauterine gestation: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36357970" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Maternal Morbidity After Double Balloon Catheter Management of Cesarean Scar and Cervical Pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32302016" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : First-trimester treatment of cesarean scar pregnancy using a cervical ripening-double-balloon catheter: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30303911" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Cesarean Scar Pregnancy, Incidence, and Recurrence: Five-Year Experience at a Single Tertiary Care Referral Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21392878" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Methotrexate therapy followed by suction curettage followed by Foley tamponade for caesarean scar pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25346492" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Foley balloon catheter to prevent or manage bleeding during treatment for cervical and Cesarean scar pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28743445" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Recap-Minimally invasive treatment for cesarean scar pregnancy using a double-balloon catheter: additional suggestions to the technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30099757" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Minimally Invasive Treatment of Cesarean Scar and Cervical Pregnancies Using a Cervical Ripening Double Balloon Catheter: Expanding the Clinical Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14678094" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Unsuccessful medical treatment of cesarean scar ectopic pregnancy with systemic methotrexate: a report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26979630" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A new minimally invasive treatment for cesarean scar pregnancy and cervical pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26794422" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Cesarean scar pregnancy: a systematic review of treatment studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19527897" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Uterine artery embolization compared with methotrexate for the management of pregnancy implanted within a cesarean scar.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31811462" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Uterine artery embolization for postpartum and postabortion hemorrhage: a retrospective analysis of complications, subsequent fertility and pregnancy outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33908615" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The Emergent Pelvic Artery Embolization in the Management of Postpartum Hemorrhage: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33971838" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : When to perform curettage after uterine artery embolization for cesarean scar pregnancy: a clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30849356" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Evidence-based guidelines for the management of abnormally invasive placenta: recommendations from the International Society for Abnormally Invasive Placenta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29890356" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Laparoscopic Resection of Cesarean Scar Ectopic Pregnancy after Unsuccessful Systemic Methotrexate Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24767660" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Cervical priming with misoprostol for the termination of cesarean scar pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29949300" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Medical management of early pregnancy failure with misoprostol with rupture of the cesarean section scar pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28666477" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Management of persistent caesarean scar pregnancy after curettage treatment failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26764166" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Surgical treatment of Cesarean scar ectopic pregnancy: efficacy and safety of ultrasound-guided suction curettage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32127144" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Risk factors of persistent cesarean scar pregnancy after dilation and curettage: a matched case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26803916" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Management of Cesarean Scar Pregnancy Using Ultrasound-Guided Dilation and Curettage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15942155" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Successful conservative treatment of a cesarean scar pregnancy with uterine artery embolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17449510" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Reproductive outcomes of women with a previous history of Caesarean scar ectopic pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15027012" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Cesarean scar pregnancy: issues in management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15548150" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Subsequent pregnancy outcome after conservative treatment of a previous cesarean scar pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33421811" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Outcome of cesarean scar pregnancy according to gestational age at diagnosis: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31788885" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Value of first-trimester ultrasound in prediction of third-trimester sonographic stage of placenta accreta spectrum disorder and surgical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18952019" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Placenta accreta and cesarean scar pregnancy: overlooked costs of the rising cesarean section rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30677186" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Early first-trimester transvaginal ultrasound is indicated in pregnancy after previous Cesarean delivery: should it be mandatory?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31840910" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Cesarean Scar Pregnancy Registry: an international research platform.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
